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Access to Biobanks:
Harmonization Across Biobank Initiatives
Michiel Verlinden,1 Herman Nys,2 Nadine Ectors,3,4 and Isabelle Huys1,5
Purpose: The current study investigates whether access arrangements relevant for biobanking contain clear
information on key access conditions. It furthermore assesses the extent to which these access conditions are
harmonized across biobank initiatives.
Methods: A comparative analysis was conducted of access arrangements developed by 26 organizations, 36
biobank networks, and 20 biobanks worldwide.
Results: The study demonstrates a lack of clear information on 21 key access conditions relevant for bio-
banking. Furthermore, it confirms that the harmonization across biobank initiatives is limited.
Conclusion: Many biobank initiatives need to be more transparent on how they apply the studied access
conditions.
Introduction
Access to human biological materials (HBMs) andassociated data stored in biobanks is crucial for bio-
medical research.1–3 Researchers need to be able to access
different collections of HBMs and data efficiently.4–6 In
order to guarantee their long-time sustainability as well as
the scientific, legal, and ethical correct use of HBMs and
data, biobanks and biobank networks need to exercise
control on the access to their resources.1,2,4,5,7,8 Taking into
account the above, it is not surprising that several organi-
zations and authors have stressed the importance of clear
and transparent rules on access.2,4,5,9–17
Previous empirical studies focused on guidelines and
policies in relation to (among others) governance, consent,
and return of incidental findings.18–23 Only a few empirical
studies have focused on access arrangements,2,4,5,11–13 such
as guidelines, best practices, opinions, policies, agreements,
etc. containing rules on access to and use of HBM and data
collections stored within biobanks (a similar definition of
access arrangements is used by Fortin et al.2 and the
OECD24).
The current study provides qualitative data on the extent
to which access arrangements contain information on 21
selected key access conditions and the level of harmoniza-
tion of these conditions.
Materials and Methods
Definitions
In this article, the term ‘organizations’ refers to ‘organi-
zations and associations not directly involved in the man-
agement of a biobank or biobank network, but active in the
development of guidelines, policies, or best practices per-
taining to access to HBMs or data or both.’ The term
‘biobank’ refers to ‘a (single) infrastructure dedicated to the
storage and provision of HBMs or data or both for research
purposes.’ The term ‘biobank network’ refers to ‘a group of
institutions who freely assume the commitment to collabo-
rate in the domain of biobanking and who (often) share the
same procedures and quality policies, and who are (or might
be) helped by a central hub for coordination in terms of
service’.7 The term ‘biobank initiatives’ covers biobanks,
biobank networks, as well as organizations. ‘Basic HBMs’
can be defined as ‘HBMs that have not been subjected to
processing or any other manipulation, except for the purpose
of storing the HBM or providing it to an applicant.’ ‘Basic
data’ is defined as ‘data that has not been subjected to
analysis or any other processing, except for the purpose of
storing the data or providing it to an applicant.’ Custo-
dianship can be defined as the ‘caretaking responsibility for
HBM and data that starts at the planning of a biobank ini-
tiative, prior to the collection, and continues through
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research use to final dissemination of research results’ (a
slightly adapted version of the definition used by R. Yassin
et al.25 and the National Cancer Institute26).
Document selection and collection
Twenty-seven international, regional, and national orga-
nizations in the European Union, the United States, Canada
and Australia were identified (see Supplementary Table S2;
supplementary material is available online at www.liebertpub
.com/bio). In addition, a literature review on access to HBMs
or data, supplemented with information from the Public Po-
pulation Project in Genomics and Society (P3G), the Bio-
banking and Biomolecular Resources Research Infrastructure
(BBMRI.ERIC), the Deutscher Ethikrat, and the Institute for
Prospective Technological Studies (IPTS) of the European
Commission’s Joint Research Centre (JRC), served as a basis
to develop an overview of 51 biobank networks and 22 bio-
banks worldwide (see Supplementary Table S1 available in
the online article at www.liebertpub.com/bio).14,27–30 The
majority of the identified biobank initiatives were established
and funded by not-for-profit institutions. Limited information
was found for biobanks funded by for-profit institutions. The
comparative study focused on access to HBMs or data or both
for purposes of biomedical research.
Access to publicly available access arrangements
Websites and (scientific) publications available in En-
glish, French, Dutch, German, or Spanish were reviewed in
order to retrieve publicly available access arrangements of
the selected biobank initiatives. In case no access arrange-
ment was found, the contact person of the biobank initiative
was contacted via e-mail with the question of whether it had
developed an access arrangement and could provide a copy
of such arrangement. In the absence of a response, one re-
minder was sent.
Identification of key access conditions
for biobanking
In a preparatory phase, international literature in relation
to access to HBMs or data was reviewed using online re-
sources (PubMed, Embase and Web of Science). The terms
‘biological specimen bank,’ ‘biobanking,’ ‘biobank,’ ‘bio-
logical repository,’ and ‘research’ were used to review these
resources. The literature2,10,12,14,21,31–33 was supplemented
with information found on the website of P3G14,27 and a
report drafted at the request of the Medical Research Council
and The Wellcome Trust.4 This allowed us to identify 21 key
conditions in relation to access to HBMs and data (Table 1).
It was decided not to focus on consent, since this has been
investigated extensively in previous studies.4,8,12,18–21
Comparative analysis of access arrangements
In the second phase (August 2011 and January 2013, at
which time two extra copies of access arrangements were
obtained), a comparative analysis was conducted of the
access arrangements. Although access arrangements of or-
ganizations, biobank networks, and biobanks may not be
entirely comparable, taking into account their different
characteristics and purposes, access arrangements for each
category of biobank initiatives influence the question of
whether access conditions are harmonized. We therefore
studied the access arrangements of all three categories of
biobank initiatives, investigating the trends and differences
within as well as between each category, and addressing the
question whether access arrangements promulgated by or-
ganizations influence those of biobank networks and indi-
vidual biobanks. First it was investigated to what extent
each of those arrangements contained information in rela-
tion to the 21 key access conditions identified in the liter-
ature review.2,4,11–14,27 If available, the information on the
key conditions was summarized and compared using pre-
defined templates. When access arrangements did not ex-
plicitly refer to one or more of the 21 access conditions
under study, the text of the arrangement was interpreted to
discover implicit information on such conditions. It cannot
be excluded that some of these interpretations might not
fully correspond with the real (unexpressed) intentions of
the concerned biobank initiative. The comparative templates
allowed us to develop qualitative data illustrating the lack of
clear information and harmonization in relation to the 21
selected access conditions (see Supplementary Table S2).
Finally, we investigated to what extent access arrangements
of biobank initiatives applied the 21 selected access condi-
tions differently, depending on whether these initiatives
were (rather) population- or hospital-integrated.
Results
We retrieved the access arrangements for 26 organiza-
tions, 36 biobank networks, and 20 biobanks. We were not
able to obtain access arrangements for one organization, 15
biobank networks, and 2 biobanks. Of those that we were
not able to obtain, thirteen access arrangements were not
publicly available, and three were under development (thus
also unavailable). One organization and one biobank did not
yet develop an access arrangement. We discovered rel-
atively few differences in how access arrangements of
population- and hospital-integrated biobank initiatives were
applied to the 21 key access conditions. Therefore we de-
cided not to focus on the distinction between those types.
Lack of clear information
An important number of access arrangements do not
contain (clear) information on how the concerned biobank
initiatives define the 21 access conditions investigated in the
current study. Hereafter, the results concerning six selected
conditions are described in detail that, according to our
analysis, represent the most remarkable findings. An over-
view of all the results of the comparative analysis can be
found in the Supplementary Table S2.
Ownership
None of the access arrangements provided that the
principal investigators became the owner of basic HBMs
and/or data that they collected and provided to the biobank
initiative.
The majority of the access arrangements that provided
access to HBM (14 organizations, 22 biobank networks, and
13 biobanks) did not stipulate whether the biobank network,
the biobank, or the principal investigator held ownership
rights in relation to the basic HBMs (Fig. 1).
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FIG. 1. Number of access ar-
rangements of organizations, bio-
bank networks, and biobanks that
provide ownership of HBM and
data at the level of the biobank
network, the biobank, or both.
Table 1. Overview of Access Conditions
1. Access to data and/or HBM Does the access arrangement apply to data, HBM or both?
2. Type of HBM To which type of HBM does the access arrangement apply?
3. Type of data To which type of data does the access arrangement apply?
4 & 5. Level of ownership of primary HBM and data Which level (biobank network, biobank or PI) holds
ownership over primary HBM and primary data?
6 & 7. Level of custodianship of HBM and data Which level (biobank network, biobank, funder or PI) holds
custodianship over HBM and data?
8. Access committees To which extent does the access arrangement provide for a
committee to decide on access to HBM, data or both?
9. Mandate access committee How is the mandate of the access committee specified in the
access arrangement?
10. Screening of scientific merit Does the access arrangement provide for a screening of the
scientific merit of access requests and how?
11. Access by industrial company What does the access arrangement provide in relation to
access by industrial companies to the HBM and/or data?
12 & 13. External/industrial applications: Different legal
conditions and fees
To which extent does the access arrangement provide
different legal conditions and fees for external or indus-
trial applications compared to internal applications?
14. Priority setting Does the access arrangement provide criteria to prioritize
parallel applications and if this would be the case, which
criteria are stipulated?
15. Intellectual property What does the access arrangement provide in relation to IP
rights held by the biobank?
16. Exclusive (access) right of applicant To which extent does the access arrangement provide the
applicants exclusive access to certain HBM and data?
17. Preferential (access) right of collector To which extent does the access arrangement provide
preferential (access) to collectors who provided HBM and
data to the biobank initiative?
18. Benefit sharing To which extent does the access arrangement stipulate an
obligation to share benefits resulting from the use of HBM
and/or data?
19. Sharing or returning research data or results To which extent does the access arrangement stipulate an
obligation to return to the biobank initiative or share with
third parties research data or results?
20. Data protection To which extent does the access arrangement provide access
to coded, anonymised or identifiable data?
21. Return and/or destruction of tissue To which extent does the access arrangement stipulate an
obligation to return and/or destroy leftover tissue?
These conditions were considered key to access, considering the high number of times they were mentioned in scientific literature and in
access arrangements.
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The majority of the access arrangements that provided for
access to data (15 organizations, 23 biobank networks, and
10 biobanks) did not stipulate whether the biobank network,
the biobank, or the principal investigator held ownership
rights in relation to the basic data (Fig. 1).
Access arrangements of 8 organizations (where 5 are
organizations from the United Kingdom) explicitly provide
that neither the biobank network, nor the biobank, nor the
principal investigator hold ownership in relation to basic
data (as such).
Level of custodianship
The level of custodianship over HBMs was not defined in
the access arrangements of 11 organizations, 6 biobank
networks, and 4 biobanks.
With respect to biobank networks, 6 out of 31 access
arrangements stipulated that the biobank network held (ex-
clusive) custodianship over HBMs, while 15 stipulated that
custodianship was held only at the level of the biobank (Fig.
2), and 4 stipulated that the biobank network and the bio-
bank shared custodianship.
The access arrangement of one biobank provided for
shared custodianship over HBMs between the biobank and
the principal investigator, while the access arrangements of
14 biobanks granted custodianship to the biobank; the ac-
cess arrangement of one biobank stipulated that the principal
investigator held custodianship over the samples collected
by him/her.
The level of custodianship over data was not defined in
access arrangements of 16 organizations, 6 biobank net-
works, and 3 biobanks.
With respect to biobank networks, 10 access arrange-
ments stipulated that custodianship was held only at the
level of the biobank network, while access arrangements of
11 biobank networks stipulated that custodianship was held
only at the level of the biobank. Access arrangements of 4
biobank networks provided that the biobank network and the
biobank shared custodianship over the data.
The results revealed an evolving trend to provide custo-
dianship to the biobank or biobank network and no longer
to principal investigators. The comparative analysis did not
provide an unambiguous answer to the question of whether
there is a tendency within biobank networks to provide
custodianship at the level of the biobank network instead of
the biobank.
Scope of custodianship
The comparative analysis revealed differences in how
access arrangements defined custodianship. The follow-
ing (common) elements were identified on the basis of
the comparison: (i) the responsibility to safeguard the con-
fidentiality, integrity, and security of the collection and the
interests of the donors. Custodianship could furthermore
consist of (ii) the right to control the preservation, access,
use, transfer, and/or disposal of collections.
Access committees
The majority of the screened access arrangements (14
organizations, 23 biobank networks and 14 biobanks; see
Supplementary Table S2) established an access committee.
One organization and one biobank network stipulated ex-
plicitly that no access committee was established.
When we looked specifically at access arrangements that
involved establishing an access committee, we noticed that
access committees of 11 organizations, 16 biobank net-
works, and 12 biobanks provided advice or decided on each
request for access (Fig. 3).
Screening of scientific merits
The comparative analysis revealed that only half of the
access arrangements (access arrangements of 11 organi-
zations, 18 biobank networks, and 11 biobanks (Fig. 4))
stipulate explicitly whether the scientific merit of access
requests is screened. One organization’s access arrangement
stated explicitly that it did not screen the scientific merits,
since it did not feel competent to conduct such screening.
Access arrangements of 8 organizations explicitly provided
extensive scientific screening, while only 4 biobanks and no
biobank networks provided such extensive screening.
FIG. 2. Number of access ar-
rangements of organizations, bio-
bank networks, and biobanks that
provide custodianship of HBM and
data at the level of the biobank
network, the biobank, the funder,
the principal investigator, or a com-
bination of those different actors.
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Sharing or returning of research results
Access arrangements of 14 organizations, 17 biobank
networks, and 15 biobanks (Fig. 5) stipulated explicitly the
obligation to share and/or return research data or results.
When focusing on biobanks considered as population-based,
9 out of 10 access arrangements provide for an obligation to
share or return research data or results.
Discussion
The comparative analysis provides empirical data on
21 selected conditions characterizing access arrangements
for biobanks. It covers access arrangements developed by
26 organizations, 36 biobank networks, and 20 biobanks
worldwide (see Supplementary Table S1 available in the
online article at www.liebertpub.com/bio). Since we did not
find evidence of trends or differences that specifically per-
tain to one of the categories of biobank initiatives, we dis-
cuss trends and differences in access arrangements for the
three categories together, without distinguishing between
them. Previous empirical studies on access arrangements
tended to focus on a limited number of access conditions or
studied a limited number of access arrangements.4,5,11–14,27
Lack of clear information
An important number of access arrangements do not
contain clear information on how the concerned biobank
initiatives define several of the 21 access conditions inves-
tigated in the current study. Such a lack of information
constitutes an important barrier for researchers who apply
for access to biobanks.1,2,4,5,11–13,16,34
Ownership or custodianship
The study revealed that the majority of the access ar-
rangements do not stipulate anything in relation to owner-
ship of HBM (and associated data). This is probably due to
the fact that it remains uncertain which ‘ownership’ rights
can be held or claimed in relation to HBMs.1,4,15,16,19,35
Opinions in scientific literature differ on whether such rights
can be held by the donor, the collector of HBM, the re-
searcher using the HBM, or a biobank.1,8,34–37
Taking into account the uncertain status of ‘ownership’ on
HBM, we suggest focusing instead on the (bundle/compilation
of) rights held by the custodian HBM or data—irrespective
of the question whether such rights could be considered as
‘ownership’ rights.25 Bjo¨rkman pointed out that rights on
HBMs could be constructed in many different ways depend-
ing on the legal relations included in the bundle of rights. She
rightfully argued that the most important question concerns
the determination of the rights to be included in such bundle.
The question of whether such a bundle of rights would con-
stitute ownership is of minor importance.38
It appeared from the comparative analysis that access
arrangements contain different definitions of the rights
FIG. 4. Number of access ar-
rangements of organizations, bio-
bank networks, and biobanks that
provide for a scientific screening of
access requests and whether an
extensive or limited screening is
provided.
FIG. 3. Number of access ar-
rangements of organizations, bio-
bank networks, and biobanks that
define the mandate of access com-
mittees and the number of access
committees that provided a man-
date to decide on each request for
access (and/or general policy is-
sues), on particular (but not each)
request for access (and/or general
policy issues), or only on (general)
policy issues.
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and obligations of custodians. Therefore, it remains—
unfortunately—difficult for an applicant to know which
rights a custodian holds over a collection of HBMs and data.
Level of custodianship: Biobank
vs. principal investigator
The evolution in the trend to provide custodianship to a
biobank or a biobank network is presumably due to the fact
that biobanks increasingly store high numbers of HBMs
and/or data, which cannot be managed in an optimal manner
by an individual researcher/collector.11,19,20,34 Custodian-
ship at the level of the biobank or biobank network can
facilitate access to HBM and data, since it is no longer
necessary to obtain approval of each individual researcher or
collector.
Level of custodianship of HBM:
Biobank network vs. biobank
Some of the studied access arrangements provide custo-
dianship at the level of the biobank network, while the
majority provides custodianship at the level of the biobank.
The different approaches might be due to the fact that some
collections were created specifically in the framework of
a biobank network. In this case, the participating biobanks
might be more willing to allow the biobank network to exer-
cise custodianship. In other networks, the individual biobanks
created collections outside the network and subsequently de-
cided to share those collections in the framework of the bio-
bank network. In this case, the individual biobanks might want
to maintain the possibility to decide on access to ‘their’ HBMs
and/or data. Both approaches can be defended, but an applicant
needs be clearly informed on whether the biobank network or
the biobank decides on access to samples and data.
Level of custodianship: Data vs. HBM
The comparison demonstrated that custodianship of data
(in contrast to custodianship of samples) is more often held
at the level of the biobank network. This might be explained
by the fact that different researchers can access data si-
multaneously. Since the biobank maintains the possibility to
access and use its ‘own’ data, it might be more comfortable
allowing the biobank network to decide which researchers
can access the data shared in the network. The sharing of
data could be facilitated by the fact that biobank networks
decide on access to data and an applicant, therefore, needs to
obtain authorization from fewer biobank initiatives.
Access committees
When biobank initiatives claim custodianship over HBM
or data, they have the responsibility to develop transparent
access arrangements and to establish access committees to
decide on access requests. Such access committees need to
ensure that HBM and data are used in accordance with the
initial consent. They furthermore verify that the HBM is
only used for research projects that demonstrate sufficient
scientific merits. It is therefore no surprise that the com-
parative analysis confirmed that the majority of the access
arrangements establish an access committee.
Screening of scientific merit and relevance
Only half of the studied access arrangements stipulate
explicitly whether the scientific merit of access requests is
screened. This is unfortunate, since applicants need to have
clear information on such screening. Screening the scientific
merits of applications can ensure that HBMs and data are
not wasted.2 This is even more the case in relation to rare
HBMs.11,39 Finally, the biobank initiative might want to
verify whether the proposed use of HBMs and data corre-
sponds with the scientific aims of the collection.11
Some biobank initiatives might not explicitly provide for
the screening of the scientific merit of access requests, since
they are of the opinion that such screening is the responsi-
bility of an ethics review board or the organization funding
the research project.4 Furthermore, access committees of
biobank initiatives might not always have the capacity and/
or specialization to screen the scientific merit of each ap-
plication; especially in view of the wide range of disciplines
of applicant researchers. We recommend that clear infor-
mation is provided to applicants on whether and how the
scientific merit of their access requests is screened.
Obligation to share or return research results
The majority of the access arrangements require the re-
turning and/or sharing of research results with the biobank
or other researchers. This might be due to the fact that an
increasing number of funding bodies require such sharing or
returning of research results. Furthermore, this could be
justified by the substantial (public) investment required to
FIG. 5. Number of access ar-
rangements of organizations, bio-
bank networks, and biobanks that
require the return to the biobank
initiative and/or the sharing with
the scientific community of re-
search results.
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collect, store, and manage in HBM and data in an optimal
manner. However, the sharing or returning of research re-
sults is only useful when the necessary capacity is available
to store, correctly interpret, and access the results.
Since researchers invest a considerable amount of time
and effort in generating research results or data, they could
be allowed, during a limited period of time, the exclusive
right to decide who has access to them.
Conclusion
Several authors active in the biobank field have pointed out
that an increased harmonization of access conditions could
facilitate access to biobanks.1,2,5,8,10,20,21,27.40 Since many ac-
cess arrangements do not contain clear information in relation
to several of these conditions, it is difficult to draw final con-
clusions on the extent of harmonization. The comparative
analysis demonstrated a lack of harmonization of access ar-
rangements in relation to the majority of the 21 examined ac-
cess conditions. It furthermore underlines that biobank
initiatives should increase their efforts to provide clear infor-
mation on their access conditions. An empirical study is cur-
rently being conducted to shed more light on how access
conditions are applied in practice. Finally, we conclude that a
complete harmonization might be neither desirable, nor feasi-
ble, considering the different nature of biobank initiatives and
the different legal frameworks applicable to these initiatives.7
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